DEA, Medical Evaluation and State Laws

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Topics
- Treatment
- Advocacy
  - Advocacy
  - Policy
  - Decriminalization
  - Programs
  - Access
  - History
  - State Laws
  - Legalization
  - Patients
  - Safety
  - More Topics like Advocacy
- Law
- Policy
- More Topics
Resources
- Webinar Series
  - Trends in Medical Cannabis & Beyond
  - See All
- White Papers/eBooks/Guides
  - Have resources to share?
    Submit Your Own!
- Widgets
  - Build a Widget
  - Build a Content Widget
Learn More
What's This?

DEA

Medical Evaluation

State Laws

Document: Barr Responses To QFR’s: CLR Digs Out The Relevant Q’s & A’s

Cannabis Law Report

JANUARY 30, 2019

To expand the number of manufacturers, the Drug Enforcement Administration (DEA) submitted a notice in the Federal Register on August 11, 2016, soliciting applications for licenses to manufacture marijuana for research purposes. Both DOJ and HHS agreed to conduct a medical and scientific evaluation of CBD independent of marijuana in 2015.

Research and Development

Research and Development DEA CBD Law

Further Consideration of the STATES Act

Cannabis Law Report

MARCH 25, 2019

The Attorney General forwards the request to the Health and Human Services Secretary and requests a scientific and medical evaluation and recommendation, as specified by 23 USC 811(b-c). The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. Emphasis added).

Banking

Banking Law Marijuana State Laws

Medical Cannabis Brief

Document: Barr Responses To QFR’s: CLR Digs Out The Relevant Q’s & A’s

Further Consideration of the STATES Act

Stay Connected